Medivolve Stock Performance
| MEDVF Stock | USD 0 0.00 0.00% |
The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and Medivolve are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Medivolve has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Medivolve is not utilizing all of its potentials. The latest stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 851.4 K | |
| Total Cashflows From Investing Activities | -626.3 K | |
| Free Cash Flow | -9.4 M |
Medivolve |
Medivolve Relative Risk vs. Return Landscape
If you would invest 0.20 in Medivolve on November 12, 2025 and sell it today you would earn a total of 0.00 from holding Medivolve or generate 0.0% return on investment over 90 days. Medivolve is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than Medivolve, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Medivolve Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Medivolve for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Medivolve can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Medivolve generated a negative expected return over the last 90 days | |
| Medivolve has some characteristics of a very speculative penny stock | |
| Medivolve has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 86.82 M. Net Loss for the year was (6.61 M) with profit before overhead, payroll, taxes, and interest of 36.57 M. | |
| Medivolve has accumulated about 5.8 M in cash with (9.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 12.0% of the company outstanding shares are owned by corporate insiders |
Medivolve Fundamentals Growth
Medivolve Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Medivolve, and Medivolve fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Medivolve Pink Sheet performance.
| Return On Equity | -1.25 | |||
| Return On Asset | 0.0165 | |||
| Profit Margin | (0.11) % | |||
| Operating Margin | 0.01 % | |||
| Current Valuation | (972.47 K) | |||
| Shares Outstanding | 27.02 M | |||
| Price To Earning | 0.37 X | |||
| Price To Book | 0.76 X | |||
| Price To Sales | 0.65 X | |||
| Revenue | 86.82 M | |||
| EBITDA | 5.15 M | |||
| Cash And Equivalents | 5.8 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 965.43 K | |||
| Debt To Equity | 0.14 % | |||
| Book Value Per Share | 0.18 X | |||
| Cash Flow From Operations | (9.32 M) | |||
| Earnings Per Share | 0.04 X | |||
| Total Asset | 59.3 M | |||
About Medivolve Performance
By analyzing Medivolve's fundamental ratios, stakeholders can gain valuable insights into Medivolve's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Medivolve has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Medivolve has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
It is a social-impact investment focused company Investing resources, funds and bandwidth for the betterment of the human condition through medical sciences, climate change and technology. Copper One Inc. was incorporated in 2005 and is headquartered in Toronto, Canada. Medivolve operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 210 people.Things to note about Medivolve performance evaluation
Checking the ongoing alerts about Medivolve for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Medivolve help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Medivolve generated a negative expected return over the last 90 days | |
| Medivolve has some characteristics of a very speculative penny stock | |
| Medivolve has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 86.82 M. Net Loss for the year was (6.61 M) with profit before overhead, payroll, taxes, and interest of 36.57 M. | |
| Medivolve has accumulated about 5.8 M in cash with (9.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 12.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Medivolve's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Medivolve's stock is overvalued or undervalued compared to its peers.
- Examining Medivolve's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Medivolve's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Medivolve's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Medivolve's pink sheet. These opinions can provide insight into Medivolve's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Medivolve Pink Sheet analysis
When running Medivolve's price analysis, check to measure Medivolve's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medivolve is operating at the current time. Most of Medivolve's value examination focuses on studying past and present price action to predict the probability of Medivolve's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medivolve's price. Additionally, you may evaluate how the addition of Medivolve to your portfolios can decrease your overall portfolio volatility.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |